(OTC BB:EWIN), (Nasdaq: GNTA), (OTC BB:EFSF) , (NASDAQ: RIMM), (NASDAQ: INTC).

RealPennies.com: Turning Pennies into dollars: (OTC BB:EWIN), (Nasdaq: GNTA), (OTC BB:EFSF) , (NASDAQ: RIMM), (NASDAQ: INTC).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://ewin.realpennies.com

eWorld Interactive, Inc. (OTC BB:EWIN.OB - News) (January 17, 2008)) is pleased to announce that the Chinese language version of its online multi-player game "BattleZone" will be publicly launched for open beta testing on January 18.

Company CEO Guy Peckham remarked, "Not only does this signify our foray into the successful monetization phase of our business, this is also an important milestone in the development of eWorld's entertainment portal. We are currently anticipating over 5 million users to participate in the open beta testing of BattleZone." The open beta phase is the next and final step towards full commercialization of the product and it allows the Company an opportunity to fully promote the game throughout eWorld's extensive distributor and internet cafe network of over 100,000 locations. This final test period stimulates consumer appetite for the game, creating early demand to promote presales of game cards through the distribution channels.

BattleZone, created by Korean game developer Sidus and adapted for the Chinese demographic by eWorld, was originally launched in a Korean language version for its home market and is a web-based, cartoon animated, multi-player game that has been in development over the past 2 years specifically for the much larger Chinese market. Users engage in a 5-10 minute battle, mostly in team-play mode, and emerge as winners or losers. Unique techniques, battle situations, character role development, competition and team play provide the foundation for a strong and loyal player community. By gaining experience and wins in the game, online characters acquire enhanced capabilities providing ongoing depth and interest. Equipment, training and skills may also be purchased by the players using their prepaid game cards.

Additional user information and access to the open-beta test site is available at eWorld Interactive's site at www.17dian.cn. The commercial launch of the game is planned to occur concurrently with the retail distribution of prepaid player cards upon completion of open beta testing.

eWorld Interactive ("eWorld") is a second-generation media and entertainment portal in Mainland China and other Asian markets. The company has assembled a portfolio of multi-media content and applications that provide advertising access to a large customer base in the region. eWorld is a compelling place for individuals to interact with top media franchises as well as create and share their videos, photos, music, and online experiences. Offline products and video production capabilities allow the company to create higher value offerings for content providers and advertisers.

For more info: http://gnta.realpennies.com
Genta Incorporated (Nasdaq: GNTA) (January 17, 2008) announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia. The Company had previously provided guidance that a final decision would be available in the fourth quarter of 2007. Genta now envisions receiving this notification later in the current quarter. Genta Incorporated engages in the identification, development, and commercialization of drugs for the treatment of cancer and related diseases in the United States. The company's research portfolio consists of two major programs: DNA/RNA Medicines and Small Molecules. The DNA/RNA Medicines program includes drugs that are based on using modifications of either DNA or RNA as drugs that can be used to treat disease. This program includes technologies, such as antisense, decoys, aptamers, and small interfering or micro RNA. Its product Genasense, designed to block the production of a protein known as Bcl-2, which is used for the treatment of malignant melanoma, chronic lymphocytic leukemia, multiple myeloma, acute myelocytic leukemia, nonsmall-cell lung cancer, prostate cancer, small-cell lung cancer, breast cancer, colorectal cancer, nonHodgkin's lymphoma, kidney cancer, pancreatic cancer, Waldenstrom's macroglobulinemia, hepatocellular carcinoma, and childhood solid tumors. The Small Molecules program includes drugs that are based on gallium-containing compounds. Its product Ganite, a phase II product that is used as a treatment for cancer-related hypercalcemia that is resistant to hydration used primarily for patients with malignant lymphoma, bladder cancer, nonHodgkin's lymphoma, and other cancer types. Genta was founded in 1988 and is based in Berkeley Heights, New Jersey.

For more info: http://efsf.realpennies.com

eFoodSafety.com (OTC BB:EFSF) (January 17, 2008) has entered the bio- and nano-technologies industry and has initiated research on nano-particle ingredients that may be incorporated in whole foods, nutraceutical products and cosmeceuticals. eFoodSafety.com, Inc., through its subsidiaries, offers technologies that enhance food and health conditions. It develops various products, including anthrax sporicidal, a germicidal cleaner, a wound care antiseptic, an herbicide, and an insect repellent. The company also distributes various products to physicians who then prescribe the products for their patients. It primarily distributes Talsyn-CI/bid scar cream that facilitates and improves the appearance, redness, and strength of scars; Cinnergen, a non prescription liquid whole food nutritional supplement that promotes glucose metabolism; and Trimmendous, a weight loss formula focusing on the body's 24-hour metabolic processes. eFoodSafety.com markets its products in the United States and internationally through various nonexclusive distribution agreements, as well as trade shows, and industry-related events and seminars. The company was incorporated in 1998 and is based in Scottsdale, Arizona.

For more info: http://rimm.realpennies.com

Research In Motion (NASDAQ: RIMM)(January 17, 2008) announced Obopay will be available for BlackBerry smartphones from (RIM). The new Obopay application for BlackBerry users provides fast, customizable access to Obopay's full suite of mobile payment services. "The typical BlackBerry user epitomizes our need for convenience as professionals and consumers. This merges perfectly with Obopay's commitment to giving people everywhere expedient means to send and receive money and pay for goods and services," said Obopay Chief Executive Officer, Carol Realini.

For more info: http://intc.realpennies.com

Intel Corporation (Nasdaq:INTC) ( January 17, 2008) board of directors has declared a 12.5 cents per share quarterly dividend on the company's common stock. The dividend will be payable on Mar. 1, 2008 to stockholders of record on Feb. 7, 2008. Intel, the world leader in silicon innovation, develops technologies, products and initiatives to continually advance how people work and live. Additional information about Intel is available at www.intel.com/pressroom and blogs.intel.com. Intel and the Intel logo are trademarks or registered trademarks of Intel Corporation or its subsidiaries in the United States and other countries.

Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com